Submission of copy of Post Buy Back Public Advertisement related to Buy back of shares of Company.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagsonpal Pharmaceuticals Ltd has completed its buyback of 16,00,000 equity shares at Rs 250 per share for a total consideration of Rs 40 crores. The tendering period ran from May 8-14, 2026, and received 4,429 valid applications for 58,73,380 shares, representing 3.67 times oversubscription. The buyback was undersubscribed in both categories - small shareholders tendered 6,40,435 shares against 2,40,975 reserved, and general category saw 52,32,945 shares tendered against 13,59,025 reserved. Settlement was completed on May 21, 2026, and share extinguishment will be completed by June 2, 2026. Post-buyback, total shares will reduce from 6,71,39,150 to 6,55,39,150. Major sellers included Authum Investment (2,20,832 shares), Manish Gupta-MD (1,45,482 shares), and Ashoka India Equity Investment Trust (1,38,380 shares).
The buyback is positive for remaining shareholders as it reduces share count and increases promoter holding from 67.71% to 69.36%. The 3.67 times oversubscription indicates strong investor demand at Rs 250 per share.